OBI Pharma, Inc. (TPEX:4174)
Taiwan
· Delayed Price · Currency is TWD 62.00
+1.90 (3.16%)
Apr 2, 2025, 1:30 PM CST
OBI Pharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -2,310 | -1,046 | -1,614 | -1,531 | -1,378 | Upgrade
|
| Depreciation & Amortization | 222.25 | 244.86 | 240.92 | 208.75 | 214.53 | Upgrade
|
| Other Amortization | - | 4.1 | 5.69 | 7.52 | 17.31 | Upgrade
|
| Loss (Gain) From Sale of Assets | -43.72 | 0.39 | -0.01 | 15.08 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 5.96 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.26 | -879.32 | 1.02 | -0.37 | -54 | Upgrade
|
| Loss (Gain) on Equity Investments | 233.18 | 163.58 | - | - | - | Upgrade
|
| Stock-Based Compensation | 63.98 | 119.2 | 149 | 54.02 | 76.82 | Upgrade
|
| Other Operating Activities | -174.04 | -201.73 | -310.03 | -195.51 | -98.03 | Upgrade
|
| Change in Accounts Receivable | 2.28 | -4.44 | 1.43 | -2.01 | 0.07 | Upgrade
|
| Change in Inventory | -1.79 | -3.96 | -9.74 | -2.2 | -3.16 | Upgrade
|
| Change in Accounts Payable | 202.98 | -0.37 | 0.62 | 0.37 | -0.02 | Upgrade
|
| Change in Unearned Revenue | 1.5 | 3.13 | 3.16 | - | -77.64 | Upgrade
|
| Change in Other Net Operating Assets | -29.84 | -57.89 | -87.84 | -1.57 | 20.75 | Upgrade
|
| Operating Cash Flow | -1,834 | -1,653 | -1,620 | -1,064 | -1,609 | Upgrade
|
| Capital Expenditures | -113.24 | -101.93 | -254.65 | -241.33 | -182.68 | Upgrade
|
| Sale of Property, Plant & Equipment | 144.63 | 0.2 | 0.05 | - | - | Upgrade
|
| Cash Acquisitions | - | - | - | 472.65 | - | Upgrade
|
| Divestitures | -30.41 | -564.08 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -6.32 | -6.23 | -45.91 | -3.86 | -2.96 | Upgrade
|
| Investment in Securities | 481.13 | -2,110 | 109.29 | -140 | - | Upgrade
|
| Other Investing Activities | 7.23 | -13.17 | 21.33 | -4.79 | -10.26 | Upgrade
|
| Investing Cash Flow | 483.02 | -2,795 | -169.89 | 82.68 | -195.9 | Upgrade
|
| Short-Term Debt Issued | 0.41 | - | 15.71 | - | 9.47 | Upgrade
|
| Long-Term Debt Issued | 100 | - | - | - | - | Upgrade
|
| Total Debt Issued | 100.41 | - | 15.71 | - | 9.47 | Upgrade
|
| Short-Term Debt Repaid | -4.31 | -11.4 | - | -9.47 | - | Upgrade
|
| Long-Term Debt Repaid | -84.44 | -51.61 | -59.31 | -58.07 | -54.6 | Upgrade
|
| Total Debt Repaid | -88.74 | -63.01 | -59.31 | -67.54 | -54.6 | Upgrade
|
| Net Debt Issued (Repaid) | 11.67 | -63.01 | -43.61 | -67.54 | -45.13 | Upgrade
|
| Issuance of Common Stock | 2,163 | 17.61 | 3,150 | 16.99 | 22.94 | Upgrade
|
| Other Financing Activities | -0 | 652.47 | 903.59 | 214.3 | 305.29 | Upgrade
|
| Financing Cash Flow | 2,175 | 607.07 | 4,010 | 163.75 | 283.09 | Upgrade
|
| Foreign Exchange Rate Adjustments | 8.4 | -0.56 | 8.53 | -8.06 | 0.54 | Upgrade
|
| Net Cash Flow | 832.77 | -3,842 | 2,229 | -826.12 | -1,522 | Upgrade
|
| Free Cash Flow | -1,947 | -1,755 | -1,874 | -1,306 | -1,792 | Upgrade
|
| Free Cash Flow Margin | -3105.95% | -4223.71% | -39786.71% | -6956.13% | -1272.04% | Upgrade
|
| Free Cash Flow Per Share | -8.34 | -7.66 | -8.44 | -6.56 | -9.02 | Upgrade
|
| Cash Interest Paid | - | 3.74 | 3.99 | 3.8 | 4.18 | Upgrade
|
| Cash Income Tax Paid | - | -7.28 | -9.56 | -15.15 | 4.39 | Upgrade
|
| Levered Free Cash Flow | -1,092 | -1,228 | -1,406 | -1,002 | -770.41 | Upgrade
|
| Unlevered Free Cash Flow | -1,085 | -1,223 | -1,403 | -999.39 | -767.8 | Upgrade
|
| Change in Net Working Capital | -294.11 | 176.88 | 171.4 | -48.01 | -25.37 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.